Aurora Investment Counsel Takes Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Aurora Investment Counsel acquired a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 54,466 shares of the company’s stock, valued at approximately $2,179,000. Amphastar Pharmaceuticals accounts for about 1.3% of Aurora Investment Counsel’s holdings, making the stock its 20th largest holding. Aurora Investment Counsel owned 0.11% of Amphastar Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Amphastar Pharmaceuticals by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 2,815,596 shares of the company’s stock valued at $174,145,000 after acquiring an additional 48,203 shares during the last quarter. TD Asset Management Inc raised its stake in Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock worth $67,663,000 after purchasing an additional 680,976 shares during the period. Epoch Investment Partners Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 35.1% in the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after purchasing an additional 280,390 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 19.7% in the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock valued at $29,616,000 after purchasing an additional 121,764 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after buying an additional 338,653 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Insiders Place Their Bets

In other news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now directly owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Rong Zhou sold 4,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the completion of the sale, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the transaction, the director now owns 75,409 shares in the company, valued at approximately $3,504,256.23. The disclosure for this sale can be found here. Insiders sold a total of 34,383 shares of company stock worth $1,524,123 in the last 90 days. 27.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

AMPH has been the topic of a number of research analyst reports. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $63.00.

Amphastar Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ AMPH opened at $48.53 on Tuesday. The stock has a fifty day moving average price of $45.39 and a 200 day moving average price of $42.71. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The company has a market cap of $2.37 billion, a P/E ratio of 16.79, a P/E/G ratio of 0.92 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. The business had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. Research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current fiscal year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.